Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.
Vistagen today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C.
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share.
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities Read More »
Direct Biologics Reports Compelling Data as ExoFlo ™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects.
Nano Labs Ltd announced today that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2023.
Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2022 Read More »
MacuHealth, the leader in innovative eye supplements, is introducing LifeMeter, a portable, non-invasive device proven to measure the presence of vital antioxidants known as carotenoids.
MacuHealth Introduces LifeMeter to Measure Carotenoid Levels in Patients Read More »
Annovis Bio, Inc. today announced that patient recruitment for the Company’s Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer’s disease (AD) remains consistent with its planned development program.
Noticias de la actualidad científica y tecnológica del 14 de abril de 2023. …
Virax Biolabs Group Limited announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
Zucara Therapeutics Inc., today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for ZT-01 for the prevention of night-time (nocturnal) hypoglycemia in patients with Type 1 Diabetes (“T1D”).
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01 Read More »
